| Safety and Preliminary Protective Efficacy of Genetically Attenuated GA2 Parasites. (NCT04577066) | Leiden University Medical Center | 2021-09-27 |
| Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria (NCT04300309) | Novartis Pharmaceuticals | 2020-12-21 |
| Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic (NCT04416945) | University of California, San Francisco | 2020-09-20 |
| Additional Screening With Sensitives RDTs and Malaria (NCT04147546) | Institut de Recherche en Sciences de la Sante, Burkina Faso | 2020-08-31 |
| Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine (NCT05192265) | University of Ibadan | 2019-05-20 |
| Diagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia (NCT03996967) | Boston University | 2019-02-11 |
| Mass Screening and Treatment for Reduction of Falciparum Malaria (NCT04093765) | University of Oxford | 2018-11-01 |
| Clinical Performance of the Histidine Rich Protein 2 (HRP2) Highly Sensitive Rapid Diagnostic Test (HS-RDT) for Malaria Diagnosis in Pregnant Women in Papua New Guinea (NCT03462615) | Foundation for Innovative New Diagnostics, Switzerland | 2018-04-01 |
| Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic (NCT03783299) | University of California, San Francisco | 2017-11-28 |
| Efficacy and Safety of Artesunate + Amodiaquine With SLD of Primaquine for Treatment of Falciparum Malaria in Zanzibar (NCT03773536) | Professor Anders Björkman | 2017-05-09 |
| SJ733 Induced Blood Stage Malaria Challenge Study (NCT02867059) | Medicines for Malaria Venture | 2016-09-13 |
| DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax (NCT02123290) | Medicines for Malaria Venture | 2016-01-01 |
| DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria (NCT02450578) | Medicines for Malaria Venture | 2015-10-01 |
| Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos (NCT02543086) | Novartis Pharmaceuticals | 2015-07-01 |
| A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S (NCT02252640) | University of Oxford | 2015-01-01 |
| Malaria in Early Life Study (NCT02001428) | Gadjah Mada University | 2014-07-21 |
| Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ Challenge (NCT02237586) | Sanaria Inc. | 2014-07-01 |
| Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis (NCT02115516) | Sanaria Inc. | 2014-04-01 |
| Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults (NCT02132299) | Sanaria Inc. | 2014-04-01 |
| A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria (NCT02044198) | University of Oxford | 2014-03-01 |
| A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S (NCT01883609) | University of Oxford | 2013-09-01 |
| Targeted Chemo-elimination (TCE) of Malaria (NCT01872702) | University of Oxford | 2013-04-01 |
| A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches Using the ChAd63 and MVA Vectors Encoding the Antigens ME-TRAP, CS and AMA1 (NCT01739036) | University of Oxford | 2013-01-01 |
| Artemisinin-resistant Malaria in Cambodia (NCT01736319) | National Institute of Allergy and Infectious Diseases (NIAID) | 2012-06-26 |
| Experimental Human Malaria Infection After Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis (NCT01236612) | Radboud University Medical Center | 2011-04-01 |
| Immunization With Different Doses of Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis (NCT01218893) | Radboud University Medical Center | 2011-04-01 |
| EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria (NCT01169077) | National Institute of Allergy and Infectious Diseases (NIAID) | 2010-08-01 |
| EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults (NCT01026246) | National Institute of Allergy and Infectious Diseases (NIAID) | 2010-06-01 |
| Phase 1 Study of the Safety and Immunogenicity of a Malaria Transmission-blocking Pfs25-Pfs25 Conjugate Vaccine (NCT00977899) | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 2009-08-20 |
| Rapid Diagnostic Tests for Assessment of Initial Clearance and Detection of Recurrent Malaria Infections (NCT01843764) | Anders Björkman | 2009-06-01 |
| Molecular Surveillance of Artemisinin Resistance Malaria in Myanmar (NCT02792816) | Department of Medical Research, Lower Myanmar | 2009-06-01 |
| Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy (NCT00701961) | Institute of Tropical Medicine, Belgium | 2008-10-01 |
| Malarial Immunity in Pregnant Cameroonian Women (NCT00593398) | University of Hawaii | 2008-09-01 |
| Hyperphenylalaninemia in Cerebral Malaria (NCT00338520) | University of Utah | 2007-10-01 |
| The Cytoadherence in Pediatric Malaria (CPM) Study (NCT00707200) | University Health Network, Toronto | 2007-10-01 |
| Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand (NCT01659281) | Armed Forces Research Institute of Medical Sciences, Thailand | 2007-09-01 |
| Plasmodium Resistance in A. Gambiae (NCT00466557) | National Institute of Allergy and Infectious Diseases (NIAID) | 2007-06-01 |
| Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali (NCT00460525) | U.S. Army Medical Research and Development Command | 2007-05-01 |
| Phase I Pediatric FMP2.1/AS02A Trial in Mali (NCT00358332) | U.S. Army Medical Research and Development Command | 2006-11-01 |
| Malaria Transmission and Immunity in Highland Kenya (NCT00393757) | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-10-01 |
| Fetal Immunity to Falciparum Malaria (NCT00314899) | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-09-15 |
| Time to Infection With Malaria Parasites (NCT00322738) | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-06-07 |
| Malaria Prevalence in Children (NCT00322816) | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-06-07 |
| RBx11160 Phase II Dose Ranging Study RBx/MMV05-06 (NCT00362050) | Medicines for Malaria Venture | 2006-06-01 |
| Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly (NCT00347555) | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-05-01 |
| Multi-Centre Trial Comparing Three Artemisinin-Based Combination Treatments on P. Falciparum Malaria (NCT00484900) | Dafra Pharma | 2006-05-01 |
| Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America (NCT00312702) | U.S. Army Medical Research and Development Command | 2006-04-01 |
| Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers (NCT00730782) | European Vaccine Initiative | 2005-11-01 |
| Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria (NCT01594931) | Medicines for Malaria Venture | 2005-07-01 |
| AMA1-C1/Alhydrogel + CpG 7909 for Malaria (NCT00344539) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-05-01 |
| CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi (NCT00125489) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-05-01 |
| Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine for Falciparum Malaria in Zanzibar, 2005 (NCT03768908) | Professor Anders Björkman | 2005-01-05 |
| Human Immunity to MSP-1 in Western Kenya (NCT00138372) | Case Western Reserve University | 2004-07-01 |
| Experimental Vaccine for Plasmodium Falciparum Malaria (NCT00340431) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-06-09 |
| Experimental Vaccine for Malaria in Adults in Mali (NCT00343005) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-04-23 |
| Trial to Assess the Efficacy of Malaria Vaccine PfCS 102 (NCT01031524) | Swiss Tropical & Public Health Institute | 2004-03-01 |
| Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India (NCT00074841) | Pfizer | 2003-09-01 |
| Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children (NCT00317473) | U.S. Army Medical Research and Development Command | 2003-06-01 |
| Comparative Evaluation of the Safety and the Efficacy of 2 Antimalarials Depending on HIV Status (NCT00304980) | Institute of Tropical Medicine, Belgium | 2003-03-01 |
| Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar (NCT03764527) | Professor Anders Björkman | 2002-11-01 |
| ICC-1132 - Candidate Vaccine Against P Falciparum Malaria (NCT00587249) | National Institute of Allergy and Infectious Diseases (NIAID) | 2002-07-01 |
| Evaluation of Safety and Efficacy of Artemether-Lumefantrine Tablets in African Infants and Children With Uncomplicated P. Falciparum Malaria (NCT00709969) | Novartis | 2002-07-01 |
| Pentoxifylline in Children With Malaria (NCT00133393) | National Institute of Allergy and Infectious Diseases (NIAID) | 2002-01-01 |
| CS DNA MVA Trial in Mampong, Ghana (NCT00377494) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Azithromycin Combination Therapy for Malaria (NCT00299208) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| SP Resistance and Falciparum Malaria Transmission (NCT00299247) | National Institute of Allergy and Infectious Diseases (NIAID) | |